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Summary. Background: The incidence of inflammatory bowel disease (IBD) increases, and thus is more common, in pregnant women. IBD is a risk factor for venous thromboembolism (VTE) but it is not clear whether IBD predisposes women to an excess risk of VTE during pregnancy and the postpartum period. Methods: This was a nationwide population-based cohort study of all deliveries during 1980-2013 in Denmark, using data from two nationwide health registries: the Danish National Patient Registry and the Medical Birth Registry. We computed incidence rates (IRs) per 1000 person-years, and crude and adjusted relative risks (RRs) with 95% confidence intervals (CIs) for VTE during pregnancy and the first 12 postpartum weeks in women with and without IBD. Results: We included 1 046 754 women with 1 978 701 deliveries. We identified 3465 VTE events during pregnancy and 1302 VTE events postpartum. The IR for VTE during pregnancy was 4.20 (95% CI, 2.83-5.58) in IBD patients and 2.41 (95% CI, 2.33-2.50) in women without IBD, corresponding to an RR of 1.72 (95% CI,
Introduction
The incidence of inflammatory bowel disease (IBD) is increasing [1, 2] . IBD is usually diagnosed at the age of peak fertility; therefore, the condition increases also among pregnant women [1, 2] . IBD is a known risk factor for both first-time and recurrent venous thromboembolism (VTE) [3] [4] [5] . Little information is available on IBD as a risk factor for VTE during pregnancy and the postpartum period. Earlier studies have shown an excess risk of VTE for IBD patients during pregnancy, but these studies are limited by imprecise estimates and potential selection bias [6] [7] [8] [9] [10] .
Venous thromboembolism remains a leading cause of maternal death, which can be prevented by prenatal identification of high-risk women [11] . Pregnant IBD patients may have an excess risk of VTE, beyond that associated with normal pregnancies [7, 12, 13] , because of higher endogenous thrombogenic potential due to the inflammatory disease itself, as well as acquired risk factors. Both in vitro studies and clinical studies have demonstrated that inflammation and coagulation are closely related [4, [14] [15] [16] . Accordingly, IBD flare-ups have been found to be associated with higher VTE risk, although this has not yet been specified in pregnant women [4, 5, [17] [18] [19] . With regard to acquired risk factors, pregnant IBD patients are often immobilized, may undergo surgery and frequently deliver by Cesarean section, all predisposing factors for VTE [6] [7] [8] [9] 20, 21] .
The present study examined risk of VTE during pregnancy and the postpartum period among patients with and without IBD, using population-based prospectively collected nationwide data with complete follow-up. Diagnosis codes for both ulcerative colitis and Crohn's disease have a high validity (positive predictive value, 90% and 97%) and are completely registered (94%) in the Danish Registries [22] . As regards diagnosis codes for VTE during pregnancy and the postpartum period, the validity is moderate to high in the Danish registries [23, 24] .
Materials and methods

Setting
We performed a nationwide population-based cohort study encompassing all pregnancies in Denmark leading to delivery during 1980-2013. All inhabitants of Denmark are given a unique Civil Personal Register (CPR) number at birth or upon immigration, enabling linkage between Danish registries at the individual level [25] . We obtained data from two Danish nationwide registries: the Danish National Patient Registry (DNPR) and the Medical Birth Registry (MBR) [26, 27] .
Cohort
We used the MBR to identify all deliveries in Denmark from 1 January 1980 through to 31 December 2013. The MBR contains prospectively collected data on all births in Denmark since 1 January 1973 [26, 27] . Data are collected by midwives and doctors attending deliveries and include information on both the mother and the newborn. We extracted information on the course of all pregnancies and deliveries, as well as on maternal smoking (available from 1991) and maternal pre-pregnancy body mass index (BMI) (available from 2004). The conception date was defined as the date of birth minus gestational age at delivery (in days) plus 14 days.
We linked data from the MBR on all deliveries with data in the DNPR to obtain information on the exposure (IBD), outcome (VTE) and covariates. The DNPR has recorded data on all admissions and discharges from Danish non-psychiatric hospitals since 1977 and from emergency room and outpatient clinic visits since 1995 [27] . Each hospital discharge or outpatient visit is recorded in the DNPR with one primary diagnosis and up to 20 secondary diagnoses classified according to the International Classification of Diseases, Eighth Revision (ICD-8) from 1977 until the end of 1993 and Tenth Revision (ICD-10) thereafter. We included all inpatient and outpatient hospital diagnoses (all available primary or secondary diagnoses recorded in the DNPR from 1 January 1980 to 31 December 2013).We did not include emergency room diagnoses because of their low positive predictive value. All diagnosis codes used in the study are provided in Table 1 .
The exposure of interest was IBD and the diagnosis date was defined as the first hospital admission date for IBD or the first outpatient clinic visit date for IBD before or after the conception date. Women whose IBD was diagnosed during a pregnancy were treated as exposed in both the current pregnancy and in subsequent pregnancies. IBD disease flares during pregnancy were defined as an acute admission during pregnancy with IBD registered as the primary or secondary diagnosis.
We defined our outcome as VTE during pregnancy or the first 12 weeks postpartum ( Table 1) . We studied both first and recurrent VTEs. We also included superficial thrombosis as an outcome because it is a marker for undiagnosed VTE and because superficial thrombosis imposes a 5-to 30-fold increased risk of deep VTE if additional VTE risk factors are present, such as surgery, hospitalization or pregnancy [28] .
The history of co-morbid conditions associated with VTE was defined from the DNPR, using data from 1980 to date of conception. Diagnosis codes used for covariates are provided in Table 1 . Assisted reproduction is a risk factor for VTE in the subsequent pregnancy and postpartum period [29] . Starting in 1999, information on assisted reproduction was available in the DNPR. We therefore obtained information on assisted reproduction within 1 year prior to the conception date.
Statistical analysis
The follow-up period for identifying VTE during pregnancy was from conception date to VTE diagnosis, delivery, death, emigration, cancer diagnoses, cardiovascular disease diagnoses or 31 December 2013, whichever came first. The follow-up period for identifying VTE after delivery was from the day after the date of delivery to VTE diagnosis, 12 weeks postpartum, death, emigration, cancer diagnoses, cardiovascular disease diagnoses or 31 December 2013, whichever came first.
We computed incidence rates (IRs) per 1000 personyears with 95% confidence intervals (CIs) of VTE during pregnancy and the first 12 weeks after delivery in women with and without IBD. Corresponding crude and adjusted relative risks with 95% CIs were estimated using modified Poisson regression, comparing women with to those without IBD. Two adjusted models were used for the analyses of VTE during pregnancy. In Model 1, we adjusted for maternal age and smoking [30] (smoking information was available for pregnancies from 1991 to 2013). In Model 2, we adjusted for maternal age, smoking and maternal prepregnancy BMI (information on BMI was available from 2004 to 2013). Estimates for VTE during the first 12 postpartum weeks were calculated in Model 3, in which we adjusted for acute/planned Cesarean section and postpartum hemorrhage in all pregnancies from 1980 to 2013. We further stratified data by presence of IBD disease flares during pregnancy.
All statistical analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC, USA).
The study was approved by the Danish Data Protection Agency (record no. 1-16-02-1-08). According to Danish law, ethical approval is not needed for studies that are entirely registry based.
Results and discussion
Our study included 1 046 754 women with a total of 1 978 701 deliveries. The distribution of age, BMI and smoking habits was similar in women with and without IBD ( Table 2 ). The frequency of Cesarean sections was higher in IBD patients. More than one-third of women with IBD experienced a flare-up during their pregnancies. We identified 3465 VTE events during pregnancy and 1302 VTE events in the first 12 weeks after delivery (Fig. 1) between IBD and VTE [14, 23, 24, 31] . IBD patients who experienced a disease flare during pregnancy had a crude RR of 2.64 (95% CI, 1.69-4.14) for VTE during pregnancy (Table 3 ). In Table 3 , the risk of VTE during pregnancy separately for ulcerative colitis and Crohn's disease, as well as with superficial thromboses excluded, is shown. Furthermore, the risk of VTE during pregnancy and postpartum is shown separately for pulmonary embolism, deep venous thrombosis of the lower extremities and for other locations (upper extremity veins, and the portal, renal, lineal and cava vein).
For VTE during the first 12 postpartum weeks, the IR was 7.03 per 1000 person-years (95% CI, 3.87-10.20) among women with IBD compared with 2.88 per 1000 person-years (95% CI, 2.72-3.04) in women without IBD. The corresponding adjusted RR (Model 3) for VTE after delivery was 2.10 (95% CI, 1.33-3.30). Adjustment for Cesarean section and postpartum hemorrhage lowered the risk of VTE after delivery slightly (Table 3) .
Our findings strengthen evidence from previous studies showing that IBD is a risk factor for VTE both during pregnancy and in the postpartum period, especially if a disease flare-up occurs [6, [8] [9] [10] . Nonetheless, the high relative risk of VTE during pregnancy and the postpartum period found in women with IBD is modest in absolute risk terms. A study by Br€ oms et al. [7, 8] reported adjusted odds ratios (aORs) for VTE during pregnancy of 3.78 (95% CI, 1.52-9.38) in ulcerative colitis and 1.26 (95% CI, 0.35-4.53) in Crohn's disease. An increased risk of VTE during disease flares was found only among ulcerative colitis patients (aOR, 25; 95% CI, 2.49-250) [8] . However, this study included only singleton deliveries and, because multiple gestation is a risk factor for VTE, it could have underestimated the absolute incidence of VTE. In studies of VTE after delivery [9, 10] , Shand et al. reported an adjusted RR of VTE of 2.05 (95% CI, 1.02-4.10), whereas Sultan et al. reported an incidence rate ratio of 4.07 (95% CI, 1.73-9.57) [10] . A study by Nguyin et al. reported an aOR for VTE after delivery of 6.12 (95% CI, 2.91-12.9) in Crohn's disease and an aOR of 8.44 (95% CI, 3.71-19.2) in ulcerative colitis [6] . VTEs treated in outpatient clinics may, however, have been missed in this study.
This study used unselected prospectively collected data from nationwide Danish health registries, which provide full coverage of all public and private hospitals and ensure complete follow-up for all Danish residents [27] . We included both inpatient admissions and outpatient visits to ensure inclusion of VTEs treated in both settings, in contrast to previous studies. We gained more statistical precision and consequently were able to provide more precise absolute and relative risk estimates compared with earlier studies, both for VTE during pregnancy and after delivery [6, [8] [9] [10] . Although misclassification was possible for VTE, it was likely to be minimal [23, 24] . IBD diagnoses generally have high validity [32] and any misclassification is likely to be non-differential and would thus tend to decrease our estimates towards the null. Unmeasured confounding as a result of a risk-lowering effect of prophylactic anticoagulant treatment and as a result of both risk-lowering and risk-increasing effects of different IBD drugs given is possible. Some detection bias as a result of increased care of pregnant women with IBD cannot entirely be ruled out. Our study highlights that VTE is a serious concern for IBD patients even during pregnancy planning [3] . Acute hospitalizations were used as a proxy for IBD flares during pregnancy. We did not have access to data on inpatient drug use, for example corticosteroids. We may have missed cases of less severe IBD flares not admitted to hospital and this could potentially contribute to overestimating the excess risk of VTE during IBD flares.
In conclusion, our study showed that IBD is a risk factor for VTE during pregnancy and the postpartum period. In addition, acute admission for IBD flares seems to be associated with an excess risk of VTE. This underlines that proper disease control before conception is pivotal in minimizing the risk of VTE.
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